Novo Nordisk expands access to weight-loss drug Wegovy through telehealth partnerships, offering discounted rates as compounded GLP-1 alternatives become less available.
First Solar cuts 2025 outlook after Q1 earnings miss, citing tariffs and market pressures, but remains optimistic about long-term growth prospects.
Novo Nordisk expands access to weight-loss drug Wegovy through telehealth partnerships, offering discounted rates as compounded GLP-1 alternatives become less available.
First Solar cuts 2025 outlook after Q1 earnings miss, citing tariffs and market pressures, but remains optimistic about long-term growth prospects.